Table 2

Therapy of human pancreatic carcinoma growing subcutaneously in nude mice

One million of Colo-357-L3.6pl cells were mixed with Matrigel (3.5 mg of Matrigel in 0.5 ml of HBSS). Each mouse underwent two s.c. injections in bilateral flank regions. Seven days later, the mice were randomly assigned to four treatment groups of 5 mice each. The first group received twice-weekly i.p. injections of LY294002 at 25 mg/kg, the second group received gemcitabine at 62 mg/kg, the third group received combination of 25 mg/kg LY294002 and 62 mg/kg gemcitabine, and the last group received 5% DMSO in HBSS as control. All mice were sacrificed after 3 weeks of treatment.

Treatment groupsTumor volume in mm3 Mean ± SD
Body weight in grams Mean ± SD
BeforeAfterBeforeAfter
Control191.8 ± 76.92314.1 ± 874.823.12 ± 3.1827.52 ± 3.26
Gemcitabine 62 mg/kg183.9 ± 67.61596 ± 350.1a23.66 ± 2.8728.18 ± 2.54
LY294002 25 mg/kg175 ± 41.11738.1 ± 387.423.09 ± 3.0828.27 ± 3.34
LY294002 25 mg/kg + Gemcitabine 62 mg/kg181.3 ± 51.31071.4 ± 224.3b22.92 ± 2.7829.3 ± 3.01
  • a P < 0.025 versus control.

  • b P < 0.0005 versus all other groups.